SCHEMBL3351891

SCHEMBL3351891

NC=CCBr

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL137154 0.71
SCHEMBL102759 0.71
SCHEMBL483199 0.71
SCHEMBL9538013 0.64
SCHEMBL5639235 0.64
SCHEMBL8404072 0.64
SCHEMBL30832 0.64
SCHEMBL5639233 0.64
SCHEMBL23367978 0.64
SCHEMBL5909144 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117186013-A Protein degradation agent with abietic acid as hydrophobic group, preparation method, pharmaceutical composition and application thereof 南开大学 2023-12-08 CN disclosed
EP-3556759-B1 HAPTENS OF PALIPERIDONE JANSSEN PHARMACEUTICA NV (BE) 2023-11-29 EP disclosed
US-11225527-B2 Antibodies to paliperidone haptens and use thereof JANSSEN PHARMACEUTICA NV (BE) 2022-01-18 US disclosed
US-10913726-B2 Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-02-09 US disclosed
US-10910634-B2 Electroactive ionic liquids and surface-modified substrates containing them UNIVERSITÉ PARIS CITÉ (FR) 2021-02-02 US disclosed
EP-3453038-B1 ELECTROACTIVE IONIC LIQUIDS AND SURFACE-MODIFIED SUBSTRATES CONTAINING THEM CENTRE NAT RECH SCIENT (FR) 2020-12-16 EP disclosed
US-10800749-B2 Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-10-13 US disclosed
US-20190338047-A1 Antibodies to Paliperidone Haptens and Use Thereof JANSSEN PHARMACEUTICA NV (BE) 2019-11-07 US disclosed
US-20190337911-A1 CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-11-07 US disclosed
EP-3556759-A1 HAPTENS OF PALIPERIDONE Janssen Pharmaceutica NV (BE) 2019-10-23 EP disclosed
US-20060289833-A1 Esters of phosphorus-oxygen acids, these esters comprising alkoxy groups, and their use as corrosion inhibitors and flameproofing agents BASF ATKIENGESELLSCHAFT (DE) 2006-12-28 US disclosed
US-20060156960-A1 Use of phosphorus-oxygen acid esters containing alkoxy groups as corrosion inhibitors for reinforced concrete SIKA TECHNOLOGY AG (CH) 2006-07-20 US disclosed
CN-1784367-A Use of phosphorus-oxygen acid esters containing alkoxy groups as corrosion inhibitors for reinforced concrete SIKA TECHNOLOGY AG (CH) 2006-06-07 CN disclosed
EP-1633365-A1 MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-15 EP disclosed
WO-2004105765-A1 MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2004-12-09 WO disclosed
EP-1083888-A1 MULTIBINDING AGENTS THAT MODULATE PPARgamma AND RXR RECEPTORS Advanced Medicine, Inc. (US) 2001-03-21 EP disclosed
WO-1999063983-A9 MULTIBINDING AGENTS THAT MODULATE PPARη AND RXR RECEPTORS ADVANCED MEDICINE INC (US) 2000-03-23 WO disclosed
WO-1999063983-A1 MULTIBINDING AGENTS THAT MODULATE PPARη AND RXR RECEPTORS ADVANCED MEDICINE, INC. (US) 1999-12-16 WO disclosed
US-5073565-A Atherosclerosis, anticholesterol WARNER-LAMBERT COMPANY (US) 1991-12-17 US disclosed
WO-1991017150-A1 TETRAZOLE UREA AND THIOUREA ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 1991-11-14 WO disclosed